LFB
1.3.2021 14:02:06 CET | Business Wire | Press release
Regulatory News:
LFB today announced that the European Medicines Agency (EMA), the European regulatory authority, has accepted for filing the Marketing Authorization Application for eptacog beta, a recombinant coagulation Factor VIIa (rFVIIa).
The application includes data from three prospective phase 3 clinical trials (PERSEPT 1, PERSEPT 2, and PERSEPT 3) assessing the efficacy and safety of eptacog beta in the treatment of bleeding episodes in children and adults with congenital haemophilia A or B with inhibitors and for the prevention of bleeding in those patients undergoing surgery or invasive procedures. The final outcome from the EMA review is expected by mid-2022.
This announcement comes less than a year after the approval in April 2020 by the United States Food and Drug Administration (FDA) of LFB’s Biologics License Application (BLA) for the coagulation factor VIIa (recombinant)-jncw (eptacog beta), under the name SEVENFACT®, for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with haemophilia A or B with inhibitors. A sBLA efficacy supplement is currently under FDA review, with a regulatory outcome expected by mid-2021. An exclusive license for the commercialization of SEVENFACT® in the USA has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.
In parallel, LFB announces the online publication of the exploratory in vitro study of eptacog beta in combination with emicizumab in the journal Haemophilia. 1 The combination of eptacog beta with emicizumab results in a concentration-dependent increase in thrombin generation in haemophilia plasma that remains below that of normal non-haemophilic plasma.
These exploratory study results provide in vitro data supporting the concept of eptacog beta use for the treatment of breakthrough bleeding in haemophilia patients treated with emicizumab. A clinical study is planned in the first quarter 2021 to further evaluate the use of SEVENFACT® in this patient population.2 The recommendation from the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation in the USA supports the use of SEVENFACT® for the treatment of breakthrough bleeding in patients using emicizumab prophylaxis.3
About the exploratory in vitro study
The aim of this study was to determine the in vitro procoagulant activity of eptacog beta and emicizumab (alone and in combination) utilizing a thrombin generation assay with haemophilia A plasma with and without inhibitors.
A significant increase in peak thrombin, endogenous thrombin potential and velocity was observed for combinations of eptacog beta (0, 1, 2 or 5 µg/mL) with emicizumab (0, 50 or 100 µg/mL) in haemophilia A and haemophilia A plasma with inhibitors; the effect remained below that observed in normal, non-haemophilic plasma.
This study was sponsored by LFB. More details can be found in the study manuscript available at https://onlinelibrary.wiley.com/doi/full/10.1111/hae.14253
About LFB
LFB is a biopharmaceutical group that develops, manufactures, and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases.
Created in France in 1994, LFB is today one of the leading European companies providing plasma-derived and recombinant medicinal products to healthcare professionals. Its mission is to offer patients new treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis and intensive care.
LFB’s current market portfolio includes 15 biomedicinal products sold in over 30 countries.
Please visit www.lfb-group.com
for additional information.
About HEMA Biologics, LLC
HEMA Biologics is a biopharmaceutical company, located in Louisville, KY. HEMA Biologics has commercialization and distribution rights for SEVENFACT® in the USA and Canada. HEMA Biologics takes pride in the heritage of LFB, the developer and manufacturer of SEVENFACT®.
The company is dedicated to meeting the needs of patients living with rare bleeding disorders, supporting the community that cares for them, and bringing meaningful products and services to the marketplace to help improve their daily lives.
Please visit www.hemabio.com
for additional information.
1
Grandoni J, Duretz V, Bonzo D, et al. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human FVIIa) and emicizumab in congenital haemophilia A plasma. Haemophilia 2021 Feb;
https://onlinelibrary.wiley.com/doi/full/10.1111/hae.14253
Online ahead of print.
2
ATHN16 study coordinated by the American Thrombosis and Hemostasis Network
: https://clinicaltrials.gov/ct2/show/NCT04647227
3
MASAC Document 263 - MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders (Revised August 2020). National Hemophilia Foundation. Available at: https://www.hemophilia.org/sites/default/files/document/files/263_treatment.pdf
last accessed on February 7, 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005514/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Chambers Organises Open Dialogue in London to Showcase Dubai’s Competitive Advantages as a Global Business Hub16.6.2026 11:25:00 CEST | Press release
Dubai Chambers organised an open dialogue in London in cooperation with the London Chamber of Commerce and Industry (LCCI) aimed at showcasing Dubai’s competitive advantages as a global business hub to a group of leading British investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616827193/en/ H.E. Mohammad Ali Rashed Lootah addresses the audience during the event (Photo: AETOSWire) The event was attended by His Excellency Mohammad Ali Rashed Lootah, President and CEO of Dubai Chambers, together with UK business leaders. Discussions highlighted the key investment opportunities Dubai offers across diverse sectors, as well as the city’s advantages as a hub for the expansion of British companies in the region and globally. The session also outlined the comprehensive support provided by Dubai Chambers to UK investors to ensure the smooth establishment and growth of their businesses in Dubai. The discussions explored how
NIQ and Unlimitail Collaborate to Deliver the Next Generation of Omnichannel Retail Media Insights & Measurement Across Retailers and Countries16.6.2026 11:00:00 CEST | Press release
Enabling advertisers to prove ROI across retailers, markets, and channels with interoperable, AI-powered measurement Retail media investment is accelerating globally, with 67% of CMOs planning to increase spending on retail media networks (RMNs) in 2026. Yet only 53% believe today's RMNs provide adequate measurement and attribution capabilities, highlighting a critical gap in proving true business impact across retailers and markets.* Today, NIQ (NYSE: NIQ), a leading consumer intelligence company, and Unlimitail, a leading retail media network, announced a strategic collaboration designed to help brands and retailers unlock a new era of retail media accountability through advanced measurement, consumer insights, interoperable data infrastructure, and AI-powered analytics. This collaboration will combine Unlimitail's extensive retail media network, which spans 21 countries, 35 retailers, more than 120 retailer websites, and over 250 million loyalty cardholders, with NIQ's industry-lead
Thredd Expands Partnership with ID DISTRIBUTION to Power Next Phase of Employee Benefits and Expense Innovation16.6.2026 11:00:00 CEST | Press release
Paris-based fintech will extend its card program into corporate expense management and support continued European expansion Thredd, the AI-first issuer processing platform, today announced an expanded partnership with ID DISTRIBUTIONthrough its flagship program Vaziva, a leading employee benefits and payments platform, to support its growth beyond consumer payments, into corporate payments, as well as their international expansion. Thredd has worked with ID DISTRIBUTIONsince 2020, supporting the company’s consumer offering in France with physical and digital card issuing and payments processing capabilities. Its Vaziva card program enables companies to digitally manage and distribute multiple types of employee benefits through a single prepaid Mastercard-branded card experience. The program supports convenient, secure card usage for employees to access and use benefits across categories including lunch, gifts, culture, holidays, and travel. With more employers seeking simpler, more dig
Eastnets Launches FinCrime Intelligence Platform to Unify Financial Crime Investigations16.6.2026 10:00:00 CEST | Press release
Eastnets, a global provider of compliance and payment solutions, today announced the launch of FinCrime Intelligence Platform (FCIP), a new investigation and orchestration layer that helps financial institutions unify financial crime operations, improve investigator productivity and gain a single view of risk across AML, sanctions, KYC and fraud. As financial crime operations grow in complexity, many institutions struggle with fragmented investigation tools and inconsistent workflows. FCIP addresses this challenge by providing a single, governed workspace for managing cases across compliance domains - without replacing existing detection systems. Eastnets’ FinCrime Intelligence Platform delivers centralised case management across AML, sanctions screening and KYC, structured, multi‑level investigative workflows with assistive, explainable AI to support, and not replace, human decision-making, providing full audit trails and management oversight. By consolidating AML, fraud, KYC, and scr
Respond.io Raises $62.5M Series B to Scale AI-Powered Customer Conversations Into North America and Europe16.6.2026 10:00:00 CEST | Press release
62.5M Series B led by Camber Partners, with existing investors participating. Respond.io is profitable with $35M ARR, 169% year-over-year growth, and a 30% profit margin. New capital will fund expansion into and mergers and acquisitions within North America and Europe. Respond.io, a customer conversation management platform, today announced a $62.5 million Series B round led by Camber Partners, with participation from Endeavor Catalyst and existing investors. What respond.io does Respond.io enables mid-market B2C businesses to grow revenue from high volumes of customer chats and calls. It unifies WhatsApp, Instagram, TikTok, Messenger, LINE, Telegram, WeChat, voice calls, email, web chat and 16 more integrations into a single platform with AI agents, automation, and CRMs. This turns fragmented customer conversations into a measurable revenue engine, purpose-built for real-world scale and complexity. The company serves industries where customers initiate conversations before buying, boo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom